Dewpoint Therapeutics Announces DPTX3496 as a Development Candidate for the Treatment of Colorectal, Breast, and Lung Cancers

Dewpoint Therapeutics, Inc. announced the nomination of a second development candidate, DPTX3496. DPTX3496 is an oral, small molecule condensate modulator targeting beta catenin to address Wnt-driven colorectal cancer, TNBC, and non-small cell lung cancer.